PMC6359864_01
Hyponatraemia during anti-MM treatment and response to tolvaptan therapy
40164_2019_128_Fig1_HTML.jpg
PMC6359864_01_40164_2019_128_Fig1_HTML.jpg
Fig1
Although hyponatraemia occurred during the first cycle of treatment on day 8 (Fig. 1), there were no significant symptoms and the full cycle of treatment was completed with plasma sodium concentration returning to 135 mmol/L prior to commencement of cycle 2. Daily tolvaptan was continued, and the rest of the cycle proceeded without further episodes of hyponatremia (Fig. 1).